[go: up one dir, main page]

MX2019009759A - Composiciones de peptido estables. - Google Patents

Composiciones de peptido estables.

Info

Publication number
MX2019009759A
MX2019009759A MX2019009759A MX2019009759A MX2019009759A MX 2019009759 A MX2019009759 A MX 2019009759A MX 2019009759 A MX2019009759 A MX 2019009759A MX 2019009759 A MX2019009759 A MX 2019009759A MX 2019009759 A MX2019009759 A MX 2019009759A
Authority
MX
Mexico
Prior art keywords
peptide compositions
stable peptide
stable
chelating
kits
Prior art date
Application number
MX2019009759A
Other languages
English (en)
Inventor
Gordon W Laurie
Marc G Odrich
Michelle Carpenter
Thomas R Gadek
Paul A Laskar
Original Assignee
Tearsolutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tearsolutions Inc filed Critical Tearsolutions Inc
Publication of MX2019009759A publication Critical patent/MX2019009759A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Esta solicitud se refiere generalmente a composiciones de péptido estables y kits que comprenden bajos niveles de agentes reguladores y quelantes, y métodos para utilizar las mismas.
MX2019009759A 2017-02-21 2018-02-20 Composiciones de peptido estables. MX2019009759A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762461467P 2017-02-21 2017-02-21
US201762530565P 2017-07-10 2017-07-10
PCT/US2018/018775 WO2018156501A1 (en) 2017-02-21 2018-02-20 Stable peptide compositions

Publications (1)

Publication Number Publication Date
MX2019009759A true MX2019009759A (es) 2020-07-27

Family

ID=63252954

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009759A MX2019009759A (es) 2017-02-21 2018-02-20 Composiciones de peptido estables.

Country Status (10)

Country Link
US (3) US20190381136A1 (es)
EP (1) EP3585412A4 (es)
JP (3) JP7223712B2 (es)
KR (2) KR20250023579A (es)
CN (2) CN118975979A (es)
AU (3) AU2018225485B2 (es)
BR (1) BR112019017275A2 (es)
CA (1) CA3054290A1 (es)
MX (1) MX2019009759A (es)
WO (1) WO2018156501A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12233108B2 (en) 2019-03-13 2025-02-25 University Of Virginia Patent Foundation Compositions and methods for promoting islet viability and enhancing insulin secretion
WO2020257327A1 (en) * 2019-06-19 2020-12-24 Tearsolutions, Inc. Constrained peptides
WO2021022045A1 (en) 2019-07-31 2021-02-04 Ecolab Usa Inc. Personal protective equipment free delimer compositions
CN112353800B (zh) * 2020-11-10 2022-06-24 华熙生物科技股份有限公司 透明质酸或其盐和/或海藻糖的组合物及其在稳定麦角硫因中的用途
US20240059767A1 (en) * 2021-01-14 2024-02-22 Hanall Biopharma Co., Ltd. Treatment of dry eye syndrome using an ophthalmic composition comprising tanfanercept
CN113209273B (zh) * 2021-04-30 2024-06-07 江苏普莱医药生物技术有限公司 一种抗菌肽涂剂及其制备方法
EP4547221A2 (en) * 2022-07-01 2025-05-07 TearSolutions, Inc. Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms
CN118903367B (zh) * 2024-09-20 2025-06-24 大连深蓝肽科技研发有限公司 中药植物类药食同源纳米活性肽制剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0958360A2 (en) 1996-12-18 1999-11-24 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
AUPO500997A0 (en) 1997-02-07 1997-03-06 Macquarie Research Limited Diagnosis of disease using tears
US7053190B2 (en) 1997-03-07 2006-05-30 Human Genome Sciences, Inc. Secreted protein HRGDF73
EP1252305A2 (en) 1999-12-08 2002-10-30 Genset Full-length human cdnas encoding potentially secreted proteins
US20040081984A1 (en) 2001-02-20 2004-04-29 Laurie Gordon W. Ocular tear growth factor-like protein
CN1700894A (zh) 2002-10-18 2005-11-23 莫利化学医药公司 使用羊毛硫抗生素治疗干眼病的方法
WO2005119899A2 (en) 2004-05-13 2005-12-15 University Of Virginia Patent Foundation Use of lacritin in promoting ocular cell survival
US20070213270A1 (en) * 2004-06-16 2007-09-13 Costantino Henry R Peptide yy formulations having increased stability and resistance to microbial agents
CA2560559C (en) * 2004-11-05 2013-07-02 Senju Pharmaceutical Co., Ltd. Aqueous intraocular penetration-promoting eye drop
EP1906986A4 (en) * 2005-06-17 2011-02-23 Regenerx Biopharmaceuticals LKKTET AND / OR LKKTNT PEPTIDE COMPOSITIONS LYOPHILIZED OR PROVIDED IN A LYOPHILIC FORM
US7932227B1 (en) 2007-09-17 2011-04-26 University Of Virginia Patent Foundation Lacritin-syndecan fusion proteins
CA2718706A1 (en) * 2008-03-19 2009-09-24 Senju Pharmaceutical Co., Ltd. Partial peptide of lacritin
MX2011013060A (es) * 2009-06-05 2012-02-28 Aciex Therapeutics Inc Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
US8518412B2 (en) * 2009-09-16 2013-08-27 Senju Pharmaceutical Co, Ltd. Partial peptide of lacritin
CA2821969A1 (en) * 2010-12-21 2012-06-28 Recopharma Ab Tear substitutes
AU2015229452B2 (en) 2014-03-12 2021-07-15 University Of Virginia Patent Foundation Compositions and methods for treating eye infections and disease

Also Published As

Publication number Publication date
AU2021221401A1 (en) 2021-09-09
US20190381136A1 (en) 2019-12-19
WO2018156501A1 (en) 2018-08-30
KR20190137788A (ko) 2019-12-11
JP2023058566A (ja) 2023-04-25
JP7223712B2 (ja) 2023-02-16
RU2019126279A (ru) 2021-03-23
AU2018225485B2 (en) 2021-05-27
CN110461350B (zh) 2024-09-24
US12064469B2 (en) 2024-08-20
EP3585412A4 (en) 2020-12-09
AU2021221401B2 (en) 2023-11-09
CN118975979A (zh) 2024-11-19
BR112019017275A2 (pt) 2020-05-12
CA3054290A1 (en) 2018-08-30
KR20250023579A (ko) 2025-02-18
AU2018225485A1 (en) 2019-09-05
JP7695277B2 (ja) 2025-06-18
EP3585412A1 (en) 2020-01-01
JP2025170781A (ja) 2025-11-19
RU2019126279A3 (es) 2021-06-02
US20250222070A1 (en) 2025-07-10
AU2024200748A1 (en) 2024-02-29
US20220305083A1 (en) 2022-09-29
CN110461350A (zh) 2019-11-15
JP2020508349A (ja) 2020-03-19

Similar Documents

Publication Publication Date Title
MX2019009759A (es) Composiciones de peptido estables.
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
CO2019002239A2 (es) Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados
UY36723A (es) Composiciones antifúngicas de methylobacterium y sus métodos de uso
CL2019002605A1 (es) Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas.
MX2019011496A (es) Composiciones de niraparib.
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
MX2020002611A (es) Activador especifico de akt3 y usos del mismo.
BR112021011124A2 (pt) Anelossomos e métodos de uso
MX2019005322A (es) Composiciones de recubrimiento y metodos de uso de las mismas.
BR112018075185A2 (pt) formulações análogas de hidróxi metionina adequadas para aplicações de produtos químicos especializados
MX391533B (es) Composiciones de saponinas y extractos vegetales.
EA202092692A1 (ru) Аналоги рапамицина и их применения
EA202090335A1 (ru) Взаимоусиливающие комбинации гербицидов
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
CO2020005625A2 (es) Combinación novedosa de defoliantes
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
CL2019003037A1 (es) Combinaciones fungicidas.
CL2019003350A1 (es) Una composición agroquímica estable y el proceso de esta.
MX2023008764A (es) Composiciones y metodos para prevenir y tratar afecciones.
BR112017018618A2 (pt) odorizante de osmanthus
CO2020003134A2 (es) Moduladores de la expresión de enac